GSK presents positive clinical data on maternal and older adults RSV candidate vaccines

▴ GSK presents positive clinical data on maternal and older adults RSV candidate vaccines
Both candidate vaccines contain a recombinant subunit pre-fusion RSV antigen which is believed to trigger the required immune response

GSK today announced that its Respiratory Syncytial Virus (RSV) candidate vaccines for maternal immunisation (GSK3888550A) and older adults (GSK3844766A) were well-tolerated and highly immunogenic in Phase I/II clinical studies. The data were presented virtually at the ID Week Congress.

RSV is a leading cause of respiratory infections such as bronchiolitis (inflammation and congestion of the small airways or bronchioles of the lung) and pneumonia (an inflammatory condition of the lung small air sacs or alveoli) in infants and older adults. It is estimated to cause about 3 million hospitalisations of children under 5 year of age globally, and 177,000 hospitalisations of older people in the US alone.

Both candidate vaccines contain a recombinant subunit pre-fusion RSV antigen (RSVPreF3) which is believed to trigger the required immune response. The vaccine for older adults also includes GSK’s proprietary AS01 adjuvant system to boost the immune response as this population tends to show weaker immune response to vaccination than younger adults.

The vaccine candidate for older adults was first tested in 48 healthy adults (18-40 years old) and then in 1,005 healthy older adults (60-80 years old) with different dosages of antigen and adjuvant compared with a placebo. The interim data 1-month post-immunisation show that:

the candidate vaccine elicited a robust humoral and cellular immunity compared with baseline a close to 10 times increase of protective antibodies (RSVPreF3 IgG and RSV-A neutralising antibodies) was induced in the vaccinated group importantly, the cellular immunity (RSVPreF3-specific CD4+ T-cells) of the vaccinated older adults was boosted to reach similar range to that observed in the younger adults after vaccination with the non-adjuvanted formulation, despite the initial lower baseline level observed in older adults compared with young adults.

The maternal RSV candidate vaccine was tested with 3 different doses compared with placebo in 502 healthy non-pregnant women over monthly visits (Day 8, Day 31 and Day 91 post immunisation). The data show that, compared with baseline:

the investigational vaccine was able to rapidly boost the pre-existing immunity at all dose levels, leading to high levels of protective neutralising antibodies. at Day 8, a 14-fold increase in RSV-A and RSV-B neutralising antibodies titers was observed.

These two vaccines are part of a tailored, portfolio approach GSK is pursuing with three RSV candidate vaccines – maternal, paediatric and older adults – using different novel technologies aiming to help protect the populations most impacted: infants and older adults. All three candidate vaccines have received FDA fast-track designation.

GSK today announced that its Respiratory Syncytial Virus (RSV) candidate vaccines for maternal immunisation (GSK3888550A) and older adults (GSK3844766A) were well-tolerated and highly immunogenic in Phase I/II clinical studies. The data were presented virtually at the ID Week Congress.

RSV is a leading cause of respiratory infections such as bronchiolitis (inflammation and congestion of the small airways or bronchioles of the lung) and pneumonia (an inflammatory condition of the lung small air sacs or alveoli) in infants and older adults. It is estimated to cause about 3 million hospitalisations of children under 5 year of age globally, and 177,000 hospitalisations of older people in the US alone.

Both candidate vaccines contain a recombinant subunit pre-fusion RSV antigen (RSVPreF3) which is believed to trigger the required immune response. The vaccine for older adults also includes GSK’s proprietary AS01 adjuvant system to boost the immune response as this population tends to show weaker immune response to vaccination than younger adults.

The vaccine candidate for older adults was first tested in 48 healthy adults (18-40 years old) and then in 1,005 healthy older adults (60-80 years old) with different dosages of antigen and adjuvant compared with a placebo. The interim data 1-month post-immunisation show that:

the candidate vaccine elicited a robust humoral and cellular immunity compared with baseline a close to 10 times increase of protective antibodies (RSVPreF3 IgG and RSV-A neutralising antibodies) was induced in the vaccinated group importantly, the cellular immunity (RSVPreF3-specific CD4+ T-cells) of the vaccinated older adults was boosted to reach similar range to that observed in the younger adults after vaccination with the non-adjuvanted formulation, despite the initial lower baseline level observed in older adults compared with young adults.

The maternal RSV candidate vaccine was tested with 3 different doses compared with placebo in 502 healthy non-pregnant women over monthly visits (Day 8, Day 31 and Day 91 post immunisation). The data show that, compared with baseline:

the investigational vaccine was able to rapidly boost the pre-existing immunity at all dose levels, leading to high levels of protective neutralising antibodies at Day 8, a 14-fold increase in RSV-A and RSV-B neutralising antibodies titers was observed.

These two vaccines are part of a tailored, portfolio approach GSK is pursuing with three RSV candidate vaccines – maternal, paediatric and older adults – using different novel technologies aiming to help protect the populations most impacted: infants and older adults. All three candidate vaccines have received FDA fast-track designation.

Tags : #LatestPhramaNewsOct21 #LatestGskNewsOct21 #Treatmentofrespiratoryinfections #bronchitis #pneumonia #immunizationbyGsk

About the Author


Sana Farid Khan

“The best way to become acquainted with a subject is to write about it."
A confident counselor, a speaker, and an educator, ready to utilize my communication skills effectively in the world of healthcare by putting pen to paper to reach new heights of success.
You can write to me at [email protected]

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

An overview of Cancer by Dr. Keyur Ghutte, Surgical OncologistFebruary 28, 2021
Abdullah Saleem, Group CIO of Omni Hospitals sheds light on how IT is going through one of its best phasesFebruary 27, 2021
Discussing Sexual Health is a Taboo! Expert Urologist, Dr.Anil Elhence sheds light upon some vital issues of sexual health concerning society as a wholeFebruary 27, 2021
27th February – Anosmia Awareness DayFebruary 27, 2021
To use my learnings to impact the lives of those who did not have the privilege to learn is most satisfying, says Saji Mathew, Chief Operating Officer, Baby Memorial HospitalFebruary 27, 2021
“I can & I will !!” - The Thought Behind Spreading Awareness of Cancer by Dr.Sachin Marda, Eminent Oncologist February 26, 2021
Get into “zen”mode for your mental health with these tips February 26, 2021
Sex Education Should be Normalized, says Dr. Shivadev M, Psychiatrist, and Sexual Wellness ExpertFebruary 26, 2021
Learn Everything about Broken Heart Syndrome. February 25, 2021
Why Should A Woman give Importance to Mental Health?February 25, 2021
Healthy Living for an Improved Cancer Scenario in India, explained by Dr. Amol Akhade, Senior Consultant Medical Oncologist, Hemato-Oncologist and Bone Marrow Transplant PhysicianFebruary 25, 2021
Dr. Latika Chawla, Obstetrician and Gynaecological Endoscopic Surgeon advises women to take care of their sexual and reproductive health and be open to discuss it with specialists without inhibitionFebruary 25, 2021
COVID-19: Maharashtra’s Latur district administration to implement 'Janata curfew' on February 27 and 28February 25, 2021
Covid-19 antibodies offers protection against reinfection later, study suggests February 25, 2021
People traveling to Delhi from states with spike in COVID-19 cases to show negative RT-PCR test from 26th FebFebruary 25, 2021
An Overview of Leprosy by Dr. Nitin Sampat, Senior NeurologistFebruary 25, 2021
India starts shipping COVID-19 vaccines to Africa under COVAX facilityFebruary 25, 2021
Govt to commence administering COVID-19 vaccine to people above 60 yrs of age from 1st MarchFebruary 24, 2021
Cabinet approves production linked incentive scheme for pharmaceuticalsFebruary 24, 2021
‘Night owls’ may be twice as likely as morning ‘larks’ to underperform at workFebruary 24, 2021